Physician profile

Mabria Loqman

Family Medicine · Racine, WI

NPI 1891862678

$2,213.16

in general payments reported to CMS, 2019-2025

20 companies · none reported in 2025

See the full distribution for Family Medicine

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $337.43 2019-2020
Amarin Pharma, INC. $269.89 2019-2020
Novo Nordisk INC $240.32 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $224.34 2019
Astrazeneca Pharmaceuticals LP $221.40 2019-2020
Amgen INC. $209.72 2019
Sanofi-Aventis U.S. LLC $166.02 2019-2020
Glaxosmithkline, LLC. $157.50 2019
Pfizer INC. $83.98 2019
Optinose US, INC. $50.68 2019
Shire North American Group INC $44.80 2019
Teva Pharmaceuticals USA, INC. $37.70 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $35.74 2019
E.R. Squibb & Sons, L.L.C. $28.72 2019
Genentech USA, INC. $24.70 2020
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Philips North America LLC $24.36 2019
Csl Behring $14.69 2019
Supernus Pharmaceuticals, INC. $14.35 2019
Horizon Therapeutics Plc $13.55 2019
Abbott Laboratories $13.27 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mabria Loqman

$2,213.16

in general payments reported 2019-2025

Years
2019-2020
Top company
Lilly USA, LLC

https://glasscript.com/doctor/131003/mabria-loqman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.